Premium
Flutamide as Primary Treatment for Metastatic Prostatic Cancer
Author(s) -
Rolf Lundgren
Publication year - 1987
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1987.tb04809.x
Subject(s) - flutamide , medicine , prostate cancer , oncology , cancer , prostate , antiandrogen , disease , urology , androgen receptor
Summary— Ten men with newly diagnosed generalised cancer of the prostate were treated with Flutamide (SCH 13521). After 18 months of treatment, one patient had stable disease and was symptom‐free. Seven patients left the study because of progression of cancer and two because of the side effects of Flutamide. None of the patients with progression showed an objective response to second‐line oestrogen therapy.